The First and Only FDA-Approved Oral Treatment for Relapsed or Refractory FLT3m+ AML1,2

Dosage and Administration

The Recommended Starting Dose of XOSPATA1

24 hours icon.

120 mg once daily

Three tablets icon.

Three 40 mg tablets

Tablets shown are not actual size.

Eating utensils icon.

With or without food

  • Response may be delayed. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response1
  • Do not break, crush, or chew XOSPATA tablets. Take whole with a cup of water1
  • Administer XOSPATA tablets orally at about the same time each day1
  • If a dose of XOSPATA is missed or not taken at the usual time1:
    • Administer the dose as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose
    • Return to the normal schedule the following day
    • Do not administer 2 doses within 12 hours
House icon.

XOSPATA may be taken at home1

  • Assess blood counts and blood chemistries, including creatine phosphokinase:
    • Prior to initiating treatment with XOSPATA
    • At least once weekly for the first month
    • Once every other week for the second month
    • Once monthly for the duration of therapy
  • Perform an ECG prior to initiation of treatment with XOSPATA, on Days 8 and 15 of the first cycle, and prior to the start of the next 2 subsequent cycles
  • Differentiation syndrome: If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days. Interrupt XOSPATA if severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids and resume XOSPATA when signs and symptoms improve to Grade 2 or lower
  • Posterior reversible encephalopathy syndrome: Discontinue XOSPATA
  • QTc interval >500 msec: Interrupt XOSPATA and resume at 80 mg dose when QTc interval returns to within 30 msec of baseline or ≤480 msec
  • QTc interval increased by >30 msec on ECG on Day 8 of first cycle: Confirm with ECG on Day 9 and, if confirmed, consider dose reduction to 80 mg
  • Pancreatitis: Interrupt XOSPATA until pancreatitis is resolved and resume at 80 mg dose
  • Other Grade ≥3 toxicity considered related to treatment: Interrupt XOSPATA until toxicity resolves or improves to Grade 1 and resume at 80 mg dose

AML=acute myeloid leukemia; ECG=electrocardiogram; FLT3=FMS-like tyrosine kinase 3; m+=mutation-positive; QTc=corrected cardiac ventricular repolarization.

References: 1. XOSPATA [package insert]. Northbrook, IL: Astellas Pharma US, Inc. 2. Ballesta-López O, Solana-Altabella A, Megías-Vericat JE, Martínez-Cuadrón D, Montesinos P. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Future Oncol (Epub) 09-25-2020.